Pancreatic cancer deaths are rising in Czechia. A new pilot aims to catch it earlier

A targeted detection project will begin in 2027 as doctors warn pancreatic cancer could become the second-leading cause of cancer deaths by 2040.

Expats.cz Staff

Written by Expats.cz Staff Published on 20.11.2026 07:55:00 (updated on 20.11.2026) Reading time: 2 minutes

Pancreatic cancer could become Czechia’s second-leading cause of cancer deaths by 2040, doctors warned Thursday, as health authorities prepare a pilot project aimed at detecting the disease earlier.

Around 2,700 people are diagnosed annually and more than 2,300 die, according to Michal Vočka of Prague’s General University Hospital, VFN. Many patients reach specialists too late for surgery.

“Initially, the symptoms are vague or absent,” Vočka said. Around half of patients already have cancer that has spread elsewhere in the body when diagnosed.

Earlier detection will focus on selected diabetes patients

The Health Ministry plans to begin examining patients in early 2027 through a project involving up to 500 general practitioners.

It will target people aged 60–78 with diabetes diagnosed within the previous three years, as well as people with prediabetes. Up to 5,000 patients are expected to participate.

Doctors will assess individual risks and arrange abdominal ultrasound examinations, with specialist investigations where appropriate. Participating GPs will contact eligible patients directly.

The project examines whether newly developed diabetes can help identify pancreatic cancer in a small subset of older patients. It does not mean that a diabetes diagnosis generally indicates cancer.

VFN diabetologist Jan Šoupal estimated that the pilot could identify approximately 30–50 pancreatic cancer cases among those examined.

According to the ministry’s project announcement, examinations will continue through June 2028. Findings could inform a future organized early-detection program.

Surgery remains crucial as new treatments emerge

Only 15–20 percent of patients have an operable tumor at diagnosis, said Jan Ulrych, head of VFN’s hepatopancreatobiliary center.

Treatment before surgery can sometimes shrink tumors enough to make an operation possible. Specialists also called for complex pancreatic procedures to be concentrated in experienced centers.

The urgency is reflected in Czech mortality figures. Pancreatic cancer caused 2,351 deaths in 2024, compared with 1,531 in 2004. It currently ranks behind lung and colorectal cancers.

Doctors also highlighted daraxonrasib, a targeted medicine developed for advanced pancreatic cancer.

The European Medicines Agency recommended its authorization in October for adults with metastatic pancreatic adenocarcinoma who have already received at least one systemic treatment.

In a 500-patient trial, median survival was 12.4 months with the drug, compared with 6.7 months with standard chemotherapy. Those results concern a specific patient group, rather than everyone diagnosed with pancreatic cancer.

Vočka said Thursday that EU approval had followed earlier this week. Czech access would still require assessment of reimbursement and availability by insurers and the State Institute for Drug Control.

Other treatments, including personalized mRNA vaccines, remain under investigation.

Did you like this article?

Czechia’s latest news

Read all the headlines
Want to see more from us? Select Expats.cz as a preferred source on Google.